)
Visual
test
Rein Therapeutics
Rein Therapeutics (RNTX) investor relations material
Rein Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Focused on developing therapies for orphan pulmonary and fibrosis indications, with LTI-03 as the lead candidate in Phase 2 trials for idiopathic pulmonary fibrosis (IPF).
LTI-01 and preclinical programs paused indefinitely due to capital constraints; resources are allocated to LTI-03.
No product revenue to date; operations funded by equity, warrants, and debt financings.
Net losses continue, with substantial doubt about ability to continue as a going concern without additional funding.
Financial highlights
Net loss for 2025 was $49.9 million, compared to $62.9 million in 2024.
Research and development expenses decreased to $11.0 million in 2025 from $14.2 million in 2024.
General and administrative expenses were $10.9 million in 2025, down from $13.9 million in 2024.
Impairment loss on intangible assets was $28.7 million in 2025, reflecting the indefinite pause of LTI-01 and preclinical programs.
Cash and cash equivalents at year-end 2025 were $3.2 million.
Outlook and guidance
Existing cash and recent financing expected to fund operations into Q2 2026, but not sufficient to complete the Phase 2 RENEW trial.
Additional capital is required to sustain operations and complete clinical development.
Initial interim topline data from the RENEW Phase 2 trial expected in Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Rein Therapeutics
- LTI-03 demonstrates strong anti-fibrotic and regenerative potential for IPF with favorable safety.RNTX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - LTI-03 reduced key fibrosis biomarkers and was well tolerated in IPF, supporting phase II trials.RNTXStudy Result14 Jan 2026
- Biopharma seeks up to $150M in securities, targeting rare lung diseases; at-the-market deal in place.RNTXRegistration Filing16 Dec 2025
- Shareholders will vote on a director election and executive pay, with enhanced governance and oversight.RNTXProxy Filing2 Dec 2025
- Shareholders will vote on directors, executive pay, and auditor ratification at the 2024 virtual meeting.RNTXProxy Filing2 Dec 2025
- Shareholders will vote on a director election and executive compensation at the 2025 annual meeting.RNTXProxy Filing2 Dec 2025
- Quorum for the annual meeting is now 40%, and the meeting is rescheduled for July 23, 2025.RNTXProxy Filing2 Dec 2025
- Annual meeting adjourned; reconvenes July 23, 2025, with all proposals unchanged.RNTXProxy Filing2 Dec 2025
- Shareholders to vote online August 20, 2024, on directors, pay, and auditor ratification.RNTXProxy Filing2 Dec 2025
Rein Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage